Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
16 Leser
Artikel bewerten:
(0)

WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology

SHANGHAI, China, May 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech , a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that it has appointed Dr. Peng Wang as Vice President of Discovery Biology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi PharmaTech, Dr. Wang was a research fellow at Schering-Plough Research Institute where he worked for 18 years with increasing responsibilities. He has extensive experience in discovery biology, including target validation research, assay development, screening, in vitro and in vivo biological and pharmacological studies, and mechanism of action and biomarker research. As a discovery team co-chair and biology group leader at Schering-Plough, Dr. Wang made significant contributions to the nomination of several development candidates, four of which are at various phases of clinical trial.

In his new role as Vice President of Discovery Biology, Dr. Wang will oversee the company's growing portfolio of discovery biology service offerings. Dr. Wang will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

"I am very delighted to welcome Dr. Wang on board at this exciting time. Dr. Wang's depth of experience will undoubtedly help the company to accelerate the development of our discovery biology services, and strengthen our medicinal chemistry and biologics discovery capabilities," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo, Japan, and has published numerous original biological research articles in the leading and peer-reviewed scientific journals.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com/ .

For more information, please contact: Sherry Shao Tel: +86-21-5046-4002 Email: pr@pharmatechs.com

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2008 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.